Overview

A class action lawsuit has been filed against TransMedics Group, Inc. (“TransMedics” or the “Company”) and certain of the Company’s former senior executive officers alleging violations of the federal securities laws.  The Company’s common stock trades on the NASDAQ under the ticker symbol “TMDX.”

The TransMedics class action lawsuit was brought on behalf of all persons and entities who purchased or otherwise acquired publicly traded TransMedics securities between February 28, 2023, and January 10, 2025, both dates inclusive (the “Class Period”).

TransMedics is a commercial-stage medical technology company transforming organ transplant therapy for end-stage organ failure patients across multiple disease states.  The Company developed the Organ Care System (“OCS”) to replace a decades-old standard of care.  The OCS represents a paradigm shift that transforms organ preservation for transplantation from a static state to a dynamic environment that enables new capabilities, including organ optimization and assessment.  The Company’s technology replicates many aspects of the organ’s natural living and functioning environment outside of the human body.  The Company also developed its National OCS Program, an innovative turnkey solution to provide outsourced organ retrieval, OCS organ management, and logistics services, to provide transplant programs in the United States with a more efficient process to procure donor organs with the OCS.  The Company’s logistics services include aviation transportation, ground transportation, and other coordination activities.

The TransMedics action lawsuit alleges that Defendants, throughout the Class Period, made false and/or misleading statements and/or failed to disclose that: (1) TransMedics used kickbacks, fraudulent overbilling, and coercive tactics to generate business and revenue; (2) TransMedics engaged in unsafe practices, hid safety issues, and generally lacked safety oversight; (3) the foregoing subjected TransMedics to heightened risk of scrutiny and regulatory risk; and (4) as a result, Defendants’ statements about TransMedics’ business, operations, and prospects were materially false and misleading and/or lacked a reasonable basis at all relevant times.  When the true details entered the market, the lawsuit claims that investors suffered damages.

*          *          *

If you purchased or otherwise acquired publicly traded TransMedics securities between February 28, 2023, and January 10, 2025, both dates inclusive, and you wish to serve as lead plaintiff in this lawsuit, we encourage you to submit your information to DiCello Levitt LLP via the form on this page. 

You can also contact DiCello Levitt partner Brian O’Mara by calling (888) 287-9005 or at [email protected]. 

The deadline to apply to the Court to serve as lead plaintiff in the TransMedics class action lawsuit is April 15, 2025.